Abstract
Safety and efficacy are crucial to achieving clinical authorization to use anticancer drugs. Nevertheless, at the regulatory level, anticancer drugs are permitted to be approved with comparatively reduced safety, using the cost/benefit aspect as criteria for the treatment, affecting oncology patients’ quality of life, who suffer the side effects, and the uncertainty of treatment efficacy. Therefore, it is critical to improve oncological therapies. Reducing toxicity and enhancing the relevant pharmacological properties of anticancer drugs are imperative. However, nanotechnology shows excellent potential for resolving this problem. Regardless, its clinical use poses regulatory challenges that, to be overcome, require guides that allow the design of nanoparticles with a higher safety profile and functionality, such as targeted drug delivery. Fortunately, there are available nanoparticle formulations of anticancer drugs in the market, under clinical stages and preclinical testing, with functional groups and components that decrease their toxicity while optimizing their function. These highlights may potentially improve the design of nanoparticle formulations of anticancer drugs to achieve a more outstanding quality of life for oncological patients under treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K (2013) Liposome: classification, preparation, and applications. Nanoscale Res Lett 8:102. https://doi.org/10.1186/1556-276X-8-102
Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. Bioeng Transl Med 1:10–29. https://doi.org/10.1002/btm2.10003
Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F (2009) The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Exp Parasitol 121:362–369. https://doi.org/10.1016/j.exppara.2008.12.015
Badiee A, Khamesipour A, Samiei A, Soroush D, Shargh VH, Kheiri MT, Barkhordari F, Robert M, Master W, Mahboudi F, Jaafari MR (2012) The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol 132:403–409. https://doi.org/10.1016/j.exppara.2012.09.001
Bello M, Rodríguez-Fonseca RA (2019) Complexation of methotrexate via ligand diffusion molecular dynamic simulations under neutral, basic, and acidic conditions. J Mol Graph Model 93:107443. https://doi.org/10.1016/j.jmgm.2019.107443
Bello M, Rodríguez-Fonseca RA, Correa-Basurto J (2020) Complexation of peptide epitopes with G4-PAMAM dendrimer through ligand diffusion molecular dynamic simulations. J Mol Graph Model 96:107514. https://doi.org/10.1016/j.jmgm.2019.107514
Bommana MM, Kirthivasan B, Gupta SS, Shikhar A, Shah A (2019) Chapter 2 – nanostructures in pharma: elixir to oral medicine. In: Nanoparticles in pharmacotherapy, 1st edn. William Andrew Publishing, Norwich, pp 23–44
Borowik A, Butowska K, Konkel K, Banasiuk R, Derewonko N, Wyrzykowski D, Davydenko M, Cherepanov V, Styopkin V, Prylutskyy Y, Pohl P, Krolicka A, Piosik J (2019) The impact of surface functionalization on the biophysical properties of silver nanoparticles. Nanomaterials (Basel) 9:973. https://doi.org/10.3390/nano9070973
Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A (2016) Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine 12:81–103. https://doi.org/10.1016/j.nano.2015.08.006
Burt NL, Surboeck B, Grisold W (2016) Chapter 14 – complications from pharmacotherapy. In: Berger MS, Weller M (eds) Handbook of clinical neurology, 1st edn. Elsevier, Amsterdam, pp 235–250. https://doi.org/10.1016/B978-0-12-802997-8.00014-1
Carter T, Mulholland P, Chester K (2016) Antibody-targeted nanoparticles for cancer treatment. Immunotherapy 8:941–958. https://doi.org/10.2217/imt.16.11
Casalini T (2021) Not only in silico drug discovery: molecular modeling towards in silico drug delivery formulations. J Control Release 332:390–417. https://doi.org/10.1016/j.jconrel.2021.03.005
Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Sun Y, Li B, Hu X, Schwarzenberger P, Paz-Ares L (2021) Pembrolizumab plus chemotherapy for chinese patients with metastatic squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep 2:100225. https://doi.org/10.1016/j.jtocrr.2021.100225
Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, Qoronfleh MW (2019) Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 23:20. https://doi.org/10.1186/s40824-019-0166-x
Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979. https://doi.org/10.1002/cncr.22867
Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty IB, Bawendi MG, Frangioni JV (2007) Renal clearance of quantum dots. Nat Biotechnol 25:1165–1170. https://doi.org/10.1038/nbt1340
Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga JOJH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V (2015) TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med 56:31–37. https://doi.org/10.2967/jnumed.114.144741
Corbo C, Molinaro R, Parodi A, Toledano F, Salvatore F, Tasciotti E (2016) The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine 11:81–100. https://doi.org/10.2217/nnm.15.188
Danhier F, Feron O, Préat (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y (2000) Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17:521–525. https://doi.org/10.1023/a:1007504613351
Dutta S, Corni S, Brancolini G (2021) Molecular dynamics simulations of a catalytic multivalent peptide-nanoparticle complex. Int J Mol Sci 22:3624. https://doi.org/10.3390/ijms22073624
Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R (2007) PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm 349:249–255. https://doi.org/10.1016/j.ijpharm.2007.07.038
Faisant N, Siepmann J, Benoit J (2002) PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci 15:355–366
Fathian KF, Derakhshandeh K, Khaleseh F, Azandaryani AH, Mansouri K, Khazaei M (2019) Active targeting carrier for breast cancer treatment: monoclonal antibody conjugated epirubicin loaded nanoparticle. J Drug Deliv Sci Technol 53:101136. https://doi.org/10.1016/j.jddst.2019.101136
Filion MC, Phillips NC (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329:345–356. https://doi.org/10.1016/s0005-2736(97)00126-0
Filion MC, Phillips NC (1998) Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm 162:159–170. https://doi.org/10.1016/S0378-5173(97)00423-7
Fülöp T, Kozma GT, Vashegyi I, Mészáros T, Rosivall L, Urbanics R, Storm G, Metselaar JM, Szebeni J (2019) Liposome-induced hypersensitivity reactions: risk reduction by design of safe infusion protocols in pigs. J Control Release 309:333–338. https://doi.org/10.1016/j.jconrel.2019.07.005
Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, Cosco D (2021) Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol 12:601626. https://doi.org/10.3389/fphar.2021.601626
Gala UH, Miller DA, Williams RO (2020) Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta Rev Cancer 1873:188319. https://doi.org/10.1016/j.bbcan.2019.188319
Gogoi M, Kumar N, Patra S (2016) Multifunctional magnetic liposomes for cancer imaging and therapeutic applications. In: Holban AM, Grumezescu G (eds) Nanoarchitectonics smart delivery drug targeting, 1st edn. Elsevier, Amsterdam, pp 743–782
Gordon S, Plüddemann A (2019) The mononuclear phagocytic system. Generation of diversity. Front Immunol 10:1893. https://doi.org/10.3389/fimmu.2019.01893
Guo S, Huang L (2014) Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv 32:778–788. https://doi.org/10.1016/j.biotechadv.2013.10.002
Hartl N, Adams F, Merkel OM (2020) From adsorption to covalent bonding: Apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood-brain barrier. Adv Ther 4:2000092. https://doi.org/10.1002/adtp.202000092
Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M (2016) Nanomedicines: from bench to bedside and beyond. AAPS J 18:1373–1378. https://doi.org/10.1208/s12248-016-9961-7
Hoogenboezem EN, Duvall CL (2018) Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev 130:73–89. https://doi.org/10.1016/j.addr.2018.07.011
Hung HI, Klein OJ, Peterson SW, Rokosh SR, Osseiran S, Nowell NH, Evans CL (2016) PLGA nanoparticle encapsulation reduces toxicity while retaining the therapeutic efficacy of EtNBS-PDT in vitro. Sci Rep 6:33234. https://doi.org/10.1038/srep33234
Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, Huang HC (2020) Immunological and toxicological considerations for the design of liposomes. Nano 10:190. https://doi.org/10.3390/nano10020190
Ishiwata H, Suzuki N, Ando S, Kikuchi H, Kitagawa T (2000) Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Release 69:139–148. https://doi.org/10.1016/s0168-3659(00)00293-5
Jiang T, Shi T, Zhang H (2019) Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol 12:93. https://doi.org/10.1186/s13045-019-0787-5
Jiao Y, Pang X, Zhai G (2016) Advances in hyaluronic acid-based drug delivery systems. Curr Drug Targets 17:720–730. https://doi.org/10.2174/1389450116666150531155200
Karimi M, Ghasemi A, Sahandi ZP, Rahighi R, Moosavi BSM, Mirshekari H, Amiri M, Shafaei PZ, Aslani A, Bozorgomid M, Ghosh D, Beyzavi A, Vaseghi A, Aref AR, Haghani L, Bahrami S, Hamblin MR (2016) Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev 45:1457–1501. https://doi.org/10.1039/c5cs00798d
Keizer HJ, Pinedo HM (1985) Cancer chemotherapy: alternative routes of drug administration. A review. Cancer Drug Deliv 2:147–169. https://doi.org/10.1089/cdd.1985.2.147. PMID: 3902195
Kim JH, Kim CS, Ignacio RM, Kim DH, Sajo ME, Maeng EH, Qi XF, Park SE, Kim YR, Kim MK, Lee KJ, Kim SK (2014) Immunotoxicity of silicon dioxide nanoparticles with different sizes and electrostatic charge. Int J Nanomedicine 9:183–193. https://doi.org/10.2147/IJN.S57934
Klapper Y, Hamad OA, Teramura Y, Leneweit G, Nienhaus GU, Ricklin D, Lambris JD, Ekdahl KN, Nilsson B (2014) Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials 35:3688–3696
Kumar R, Dalvi SV, Siril PF (2020) Nanoparticle-based drugs and formulations: current status and emerging applications. ACS Appl Nano Materials 3:4944–4961. https://doi.org/10.1021/acsanm.0c00606
Landesman-Milo D, Peer DJ (2012) Altering the immune response with lipid-based nanoparticles. Control Release 161:600–608
Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241–250
Lee YK, Choi EJ, Webster TJ, Kim SH, Khang D (2014) Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomedicine 10:97–113. https://doi.org/10.2147/IJN.S72998
Lentz BR (2003) Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 42:423–438. https://doi.org/10.1016/s0163-7827(03)00025-0
Liang X, Wang H, Grice JE, Li L, Liu X, Xu ZP, Roberts MS (2016) Physiologically based pharmacokinetic model for long-circulating inorganic nanoparticles. Nano Lett 16:939–945. https://doi.org/10.1021/acs.nanolett.5b03854
Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3:703–717. https://doi.org/10.2217/17435889.3.5.703
Luo ZL, Jiang JW (2012) pH-sensitive drug loading/releasing in amphiphilic copolymer PAE-PEG: integrating molecular dynamics and dissipative particle dynamics simulations. J Control Release 162:185–193
Lv H, Zhang S, Wang B, Cui S, Yan J (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114:100–109. https://doi.org/10.1016/j.jconrel.2006.04.014
Malaspina DC, Longo G, Szleifer I (2017) Behavior of ligand binding assays with crowded surfaces: molecular model of antigen capture by antibody-conjugated nanoparticles. PLoS One 12:e0185518. https://doi.org/10.1371/journal.pone.0185518
Mehrotra S, Sharma MR, Gray E, Kehua W, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV (2017) Kinetic-pharmacodynamic model of chemotherapy-induced peripheral neuropathy in patients with metastatic breast cancer treated with paclitaxel, nab-paclitaxel, or ixabepilone: CALGB 40502 (Alliance). AAPS J 19:1411–1423. https://doi.org/10.1208/s12248-017-0101-9
Mihlon F, Ray CE, Messersmith W (2010) Chemotherapy agents: a primer for the interventional radiologist. Semin Interv Radiol 27:384–390. https://doi.org/10.1055/s-0030-1267852
Moros M, Mitchell SG, Grazú V, de la Fuente JM (2013) The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome. Curr Med Chem 20:2759–2778. https://doi.org/10.2174/0929867311320220003
Mu Q, Wang H, Zhang M (2017) Nanoparticles for imaging and treatment of metastatic breast cancer. Expert Opin Drug Deliv 14:123–136. https://doi.org/10.1080/17425247.2016.1208650
Najahi-Missaoui W, Arnold RD, Cummings BS (2020) Safe nanoparticles: are we there yet? Int J Mol Sci 22:385. https://doi.org/10.3390/ijms22010385
Narvekar M, Xue HY, Eoh JY, Wong HL (2014) Nanocarrier for poorly water-soluble anticancer drugs barriers of translation and solutions. AAPS PharmSciTech 15:822–833. https://doi.org/10.1208/s12249-014-0107-x
Nguyen T, Tran VT, Duan W, Tran P, Tran T (2017) Nanoprecipitation for poorly water-soluble drugs. Curr Drug Metab 18:1000–1015. https://doi.org/10.2174/1389200218666171004112122
Olusanya TOB, Haj ARR, Ibegbu DM, Smith JR, Elkordy AA (2008) Liposomal drug delivery systems and anticancer drugs. Molecules 23:907. https://doi.org/10.3390/molecules23040907
Pagano RE, Huang L (1975) Interaction of phospholipid vesicles with cultured mammalian cells. II. Studies of mechanism. J Cell Biol 67:49–60. https://doi.org/10.1083/jcb.67.1.49
Papahadjopoulos D, Poste G, Schaeffer BE (1973) Fusion of mammalian cells by unilamellar lipid vesicles: influence of lipid surface charge, fluidity, and cholesterol. Biochim Biophys Acta 323:23–42. https://doi.org/10.1016/0005-2736(73)90429-x
Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D (2008) Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 68:1970–1978. https://doi.org/10.1158/0008-5472.CAN-07-6102
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, Hermes B, Cicin I, Medgyasszay B, Rodríguez-Cid J, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15:1657–1669. https://doi.org/10.1016/j.jtho.2020.06.015
Price G, Patel DA (eds) (2022) Drug bioavailability. StatPearls Publishing, Treasure Island, FL
Remes A, Williams DF (1992) Immune response in biocompatibility. Biomaterials 13:731–743. https://doi.org/10.1016/0142-9612(92)90010-l
Riaz MK, Riaz MA, Zhang X, Lin C, Wong KH, Chen X, Zhang G, Lu A, Yang Z (2018) Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci 19:195. https://doi.org/10.3390/ijms19010195
Rodríguez-Fonseca RA, Bello M, Rojas-Hernández S, García-Machorro J, Gutiérrez-Sánchez M, Estrada-Pérez AR, Fragoso-Vázquez MJ, Méndez-Méndez JV, Correa-Basurto J (2020) In silico and in vivo studies of gp120-HIV-derived peptides in complex with G4-PAMAM dendrimers. RSC Adv 10:20414–20426. https://doi.org/10.1039/D0RA00840K
Salahpour AF (2019) Active targeting drug delivery nanocarriers: ligands. Nano Struct Nano Objects 19:100370. https://doi.org/10.1016/j.nanoso.2019.100370
Salinger AG, Burello E, Worth A (2008) Review of computational approaches for predicting the physicochemical and biological properties of nanoparticles. JRC Sci Tech Reports EUR 23974-2009
Sanità G, Carrese B, Lamberti A (2020a) Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front Mol Biosci 7:587012. https://doi.org/10.3389/fmolb.2020.587012
Sanità G, Armanetti P, Silvestri B, Carrese B, Calì G, Pota G, Pezzella A, d’Ischia M, Luciani G, Menichetti L, Lamberti A (2020b) Albumin-modified melanin-silica hybrid nanoparticles target breast cancer cells via a SPARC-dependent mechanism. Front Bioeng Biotechnol 8:765. https://doi.org/10.3389/fbioe.2020.00765
Scholar E (2007) Alkylating agents. In: xPharm: the comprehensive pharmacology reference, 1st edn. Elsevier, Omaha, pp 1–4
Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S (2010) Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine 5:525–532
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE (2019) OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol 30:297–302. https://doi.org/10.1093/annonc/mdy522
Senapati S, Mahanta AK, Kumar S, Maiti P (2018) Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 3:7. https://doi.org/10.1038/s41392-017-0004-3
Sharma A, Madhunapantula SV, Robertson GP (2012) Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol 8:47–69. https://doi.org/10.1517/17425255.2012.637916
Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS (2021) Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 7:421–427. https://doi.org/10.1001/jamaoncol.2020.7328
Song G, Petschauer JS, Madden AJ, Zamboni WC (2014) Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases. Curr Rheumatol Rev 10:22–34. https://doi.org/10.2174/1573403x10666140914160554. PMID: 25229496
Spagnou S, Miller AD, Keller M (2004) Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43:13348–13356. https://doi.org/10.1021/bi048950a
Stuurman FE, Nuijen B, Beijnen JH, Schellens JH (2013) Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet 52:399–414. https://doi.org/10.1007/s40262-013-0040-2. PMID: 23420518
Su C, Liu Y, Li R, Wu W, Fawcett JP, Gu J (2019) Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems. Adv Drug Deliv Rev 143:97–114. https://doi.org/10.1016/j.addr.2019.06.008
Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X (2019) Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev 48:2967–3014. https://doi.org/10.1039/c8cs00805a
Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH (2017) Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 5(12):1152–1161. https://doi.org/10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6. PMID: 29109077. PMCID: PMC5712264
Thoriq S, Kerwin KZ, Yong Z (2017) Advancements in microfluidics for nanoparticle separation. Lab Chip 17(1):11–33. https://doi.org/10.1039/C6LC01045H
Tran T, Tran P (2019) Nanoconjugation and encapsulation strategies for improving drug delivery and therapeutic efficacy of poorly water-soluble drugs. Pharmaceutics 11(7):325. https://doi.org/10.3390/pharmaceutics11070325
Wang B, He X, Zhang Z, Zhao Y, Feng W (2013) Metabolism of nanomaterials in vivo: blood circulation and organ clearance. Acc Chem Res 19:761–769. https://doi.org/10.1021/ar2003336
Wang W, Sedykh A, Sun H, Zhao L, Russo DP, Zhou H, Yan B, Zhu H (2017) Predicting nano-bio interactions by integrating nanoparticle libraries and quantitative nanostructure activity relationship modeling. ACS Nano 11(12):12641–12649. https://doi.org/10.1021/acsnano.7b07093
Wei L, Lu J, Xu H, Patel A, Chen ZS, Chen G (2015) Silver nanoparticles: synthesis, properties, and therapeutic applications. Drug Discov Today 20(5):595–601. https://doi.org/10.1016/j.drudis.2014.11.014
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW (2016) Analysis of nanoparticle delivery to tumours. Nat Rev Mater 1:16014. https://doi.org/10.1038/natrevmats.2016.14
Woeppel KM, Cui XT (2021) Nanoparticle and biomolecule surface modification synergistically increases neural electrode recording yield and minimizes inflammatory host response. Adv Healthc Mater 10:e2002150. https://doi.org/10.1002/adhm.202002150
Xue S, Xiyang L, Tingting L, Yin C, Yang C, Pan Z, Lin Z, Hong Y, Chunhui W, Shengqi D, Yiyao L (2021) Recent advancements in serum albumin-based nanovehicles toward potential cancer diagnosis and therapy. Front Chem 9. ISSN=2296-2646. https://doi.org/10.3389/fchem.2021.746646
Yin WM, Li YW, Gu YQ, Luo M (2020) Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacol Sin 41(7):902–910. https://doi.org/10.1038/s41401-020-0417-3
Yue L, Sun C, Cheng Q, Ding Y, Wei J, Wang R (2019) Gold nanorods with a noncovalently tailorable surface for multi-modality image-guided chemo-photothermal cancer therapy. Chem Commun 55:13506–13509. https://doi.org/10.1039/c9cc07131h
Zeng SW, Ji Y, Shen Y, Zhu RY, Wang XG, Chen L, Chen JL (2020) Molecular dynamics simulations of loading and unloading of drug molecule bortezomib on graphene nanosheets. RSC Adv 10:8744–8750
Zhang A, Meng K, Liu Y, Pan Y, Qu W, Chen D, Xie S (2020a) Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences. Adv Colloid Interf Sci 284:102261. https://doi.org/10.1016/j.cis.2020.102261
Zhang X, Guo X, Kang X, Yang H, Guo W, Guan L, Wu H, Du L (2020b) Surface functionalization of Pegylated gold nanoparticles with antioxidants suppresses nanoparticle-induced oxidative stress and neurotoxicity. Chem Res Toxicol 33:11. PMID: 32125152
Zhu Q, Qi H, Long Z (2016) Extracellular control of intracellular drug release for enhanced safety of anti-cancer chemotherapy. Sci Rep 6:28596. https://doi.org/10.1038/srep28596
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2024 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Rodríguez-Fonseca, R.A., Macías-Pérez, M.E., Hernández-Rodríguez, M., Tolentino López, L.E., Castañeda-Delgado, J.E. (2024). Clinical and Structural Highlights for Nanoparticle Formulations of Anticancer Drugs. In: Sobti, R.C., Ganguly, N.K., Kumar, R. (eds) Handbook of Oncobiology: From Basic to Clinical Sciences. Springer, Singapore. https://doi.org/10.1007/978-981-99-6263-1_67
Download citation
DOI: https://doi.org/10.1007/978-981-99-6263-1_67
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-6262-4
Online ISBN: 978-981-99-6263-1
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences